{"entity":{"id":"nct07529717","kind":"trial","name":"First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer","aka":[],"tldr":"A phase 1/2 trial of AZD8359 in prostate cancer, run by AstraZeneca, now recruiting.","summary":"First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer is a phase 1/2 interventional study registered as NCT07529717 by AstraZeneca, with 42 participants planned, started 2026-05-18 and due to reach its primary completion in 2027-11-17. Interventions recorded: AZD8359.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07529717","url":"https://clinicaltrials.gov/study/NCT07529717"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07529717","phase":"1/2","setting":"Phase I/II Dose Escalation & Dose Optimization Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD8359, a CD8-guided T Cell-engaging Antibody That Targets STEAP2, in Adult Participants With Prostate Cancer","sponsor":"AstraZeneca","enrolled":42,"outcomes":[]},"route":"/trials/nct07529717/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}